New data from Novo Nordisk’s phase 3 trial of an oral ... 46 weeks of treatment with their dual glucagon/GLP1 agonist survodutide (BI 456906) given as a weekly subcutaneous injection resulted ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

$ 84.38-0.07-0.08% ...